Attached files

file filename
8-K/A - UV FLU TECHNOLOGIES INCv210450_8ka.htm
EX-99.1 - UV FLU TECHNOLOGIES INCv210450_ex99-1.htm
 
Pro forma financial statements
 
The unaudited pro forma consolidated balance sheet and statement of operations for the year ended September 30, 2010 combine the historical results of UV Flu Technologies, Inc. and the audited results of RxAir Industries, LLC and gives effect to the acquisition as if it occurred on October 1, 2009. Pro forma adjustments have been made. The pro forma consolidated results do not purport to be indicative of results that would have occurred had the acquisition been in effect for the periods presented, nor do they claim to be indicative of the results that will be obtained in the future, and do not include any adjustments for cost savings or other synergies achieved in the consolidations of the companies.
 
RxAir Industries, LLC was started on September 9, 2009 and had only 21 days of minimal operations for the year ended September 30, 2009. Therefore, The proforma consolidated balance sheet and statement of operations would be the materially the same as the balance sheet and statement of operations of UV Flu Technologies as of and for the year ended September 30, 2009.
 
 
 

 

UV Flu Technologies, Inc.
Balance Sheets
September 30, 2010

   
UVFT
   
RxAir
   
Eliminations
   
Pro Forma
 
                         
Assets
                       
                         
Current assets:
                       
Cash
  $ -     $ 5,177     $ -     $ 5,177  
Accounts receivable
    7,404       3,946       -       11,350  
Prepaid expenses
    95,908       -       -       95,908  
Inventory
    66,815       45,886       -       112,701  
Total current assets
    170,127       55,009       -       225,136  
                                 
Fixed assets, net of accumulated depreciation of $627
    -       2,420       -       2,420  
                                 
Other assets:
                               
Deposits
    -       4,380       -       4,380  
Trademark
    -       950       -       950  
Total other assets
    -       5,330       -       5,330  
                              -  
Total Assets
  $ 170,127     $ 62,759     $ -     $ 232,886  
                                 
Liabilities and Stockholders' Equity
                               
                                 
Current liabilities
                               
Accounts payable and accrued expenses
  $ 149,775     $ 36,090     $ -     $ 185,865  
Note payable
    541,864       16,879       -       558,743  
Total current liabilities
    691,639       52,969       -       744,608  
                              -  
Long term debt
    -       16,382       -       16,382  
                                 
Commitments and contingencies:
                               
Stockholders' equity:
                               
Common stock, $0.001 par value, 75,000,000 shares authorized, 45,080,000 shares issued and outstanding
    45,080       -               45,080  
Additional paid-in capital
    128,420       100               128,520  
Accumulated (deficit)
    (695,012 )     (6,692 )             (701,704 )
Total stockholders' equity
    (521,512 )     (6,592 )     -       (528,104 )
                              -  
Total Liabilities and Stockholders' Equity
  $ 170,127     $ 62,759     $ -     $ 232,886  

 
 

 

UV Flu Technologies, Inc.
Statements of Operations
For the Year Ended September 30, 2010

   
UVFT
   
RxAir
   
Eliminations
   
Proforma
 
                         
Revenue
  $ 107,703     $ 171,743     $ -     $ 279,446  
                                 
Cost of Sales
    85,582       29,179       -       114,761  
                                 
Gross profit
    22,121       142,564       -       164,685  
                                 
Expenses:
                               
General and administrative
    566,728       147,579       -       714,307  
Total expenses
    566,728       147,579       -       714,307  
                                 
Net operating (loss)
    (544,607 )     (5,015 )     -       (549,622 )
                                 
Other income (expense):
                               
Interest expense
    (22,659 )     (1,677 )     -       (24,336 )
Gain on sale of assets
    1,116       -       -       1,116  
Other
    (3 )     -       -       (3 )
Total other income (expense)
    (21,546 )     (1,677 )     -       (23,223 )
                                 
Total loss
  $ (566,153 )   $ (6,692 )   $ -     $ (572,845 )